Free Trial
NASDAQ:TPST

Tempest Therapeutics (TPST) Stock Price, News & Analysis

Tempest Therapeutics logo
$10.53 +1.05 (+11.08%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$10.62 +0.10 (+0.90%)
As of 08/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tempest Therapeutics Stock (NASDAQ:TPST)

Key Stats

Today's Range
$9.30
$10.90
50-Day Range
$6.25
$10.53
52-Week Range
$5.33
$20.67
Volume
223,029 shs
Average Volume
103,767 shs
Market Capitalization
$46.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Moderate Buy

Company Overview

Tempest Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

TPST MarketRank™: 

Tempest Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 657th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tempest Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tempest Therapeutics has received no research coverage in the past 90 days.

  • Read more about Tempest Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Tempest Therapeutics are expected to grow in the coming year, from ($1.39) to ($1.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tempest Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tempest Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tempest Therapeutics has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.72% of the float of Tempest Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tempest Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tempest Therapeutics has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tempest Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Tempest Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.72% of the float of Tempest Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tempest Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tempest Therapeutics has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Tempest Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Tempest Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for TPST on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.70% of the stock of Tempest Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 22.52% of the stock of Tempest Therapeutics is held by institutions.

  • Read more about Tempest Therapeutics' insider trading history.
Receive TPST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPST Stock News Headlines

New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.
See More Headlines

TPST Stock Analysis - Frequently Asked Questions

Tempest Therapeutics' stock was trading at $10.8485 on January 1st, 2025. Since then, TPST shares have decreased by 2.9% and is now trading at $10.53.

Tempest Therapeutics, Inc. (NASDAQ:TPST) issued its quarterly earnings results on Monday, August, 11th. The company reported ($2.07) EPS for the quarter, beating analysts' consensus estimates of ($3.23) by $1.16.

Tempest Therapeutics shares reverse split on the morning of Friday, June 25th 2021.The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Top institutional investors of Tempest Therapeutics include Versant Venture Management LLC (7.33%), Geode Capital Management LLC (0.94%), Group One Trading LLC and Belvedere Trading LLC. Insiders that own company stock include Versant Venture Capital Vi, L, Stephen R Brady, Justin Trojanowski and Samuel Whiting.
View institutional ownership trends
.

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tempest Therapeutics investors own include Meta Platforms (META), Cloudflare (NET), NVIDIA (NVDA), Snowflake (SNOW), Tesla (TSLA), Intel (INTC) and Pfizer (PFE).

Company Calendar

Last Earnings
8/11/2025
Today
8/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TPST
CIK
1544227
Fax
N/A
Employees
20
Year Founded
2012

Price Target and Rating

High Price Target
$65.00
Low Price Target
$9.00
Potential Upside/Downside
+184.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($14.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$41.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-334.76%
Return on Assets
-130.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.12
Quick Ratio
1.70

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.20 per share
Price / Book
4.79

Miscellaneous

Outstanding Shares
4,440,000
Free Float
4,231,000
Market Cap
$46.75 million
Optionable
Optionable
Beta
-1.93

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:TPST) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners